Clinical experience of Berlitione® use in liver diseases

In a study including 52 patients assessed the Berlition ® 300 (Berlin-Chemie AG/Menarini Group company, Germany) efficacy in the treatment of chronic liver diseases. The results of treatment confirm the positive effect of the drug Berlition ® on the functional state of the liver in patients with chronic lesions of different etiology, which was seen as significant improvement in clinical condition, the normalization of the functional "hepatic indices, decrease of cholesterol and glucose levels, significant improvement of quality of life in patients. Only one patient had moderate changes in some biochemical parameters after treatment.

non-alcoholic fatty liver disease, hepatic steatosis, steatohepatitis, viral hepatitis, drug liver damage, Gilbert's syndrome, alpha-lipoic acid